← All trials
NCT05771896
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2023
- Primary completion
- Dec 31, 2028
- Completion date
- Apr 30, 2029
- First posted
- Mar 16, 2023
- Last posted
- Sep 14, 2023
- Enrollment
- 0
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Fundacion GenesisCareLead sponsor
- BayerCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.